Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.36 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | FURIN | P09958 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19869062 | 1.00 | FOLH1 (0.40) | FOLH1CYP3A4FAPTTRKISS1R | |
| SCHEMBL25833839 | 0.94 | CYP3A4 (0.41) | FOLH1CYP3A4FAPTTRKISS1R | |
| SCHEMBL25829056 | 0.92 | CYP3A4 (0.40) | FOLH1CYP3A4FAPTTRKISS1R | |
| SCHEMBL22241542 | 0.92 | CYP3A4 (0.37) | FOLH1CYP3A4FAPTTRL3MBTL1 | |
| SCHEMBL20095333 | 0.92 | CYP3A4 (0.37) | FOLH1CYP3A4FAPTTRL3MBTL1 | |
| SCHEMBL21444704 | 0.91 | FOLH1 (0.38) | FOLH1CYP3A4FAPTTRKISS1R | |
| SCHEMBL27349556 | 0.89 | FOLH1 (0.40) | FOLH1CYP3A4FAPTTRKISS1R | |
| SCHEMBL27352417 | 0.88 | FOLH1 (0.40) | FOLH1CYP3A4FAPTTRFURIN | |
| SCHEMBL20177248 | 0.88 | FOLH1 (0.34) | FOLH1CYP3A4FAPSIRT2SIRT1 | |
| SCHEMBL23181690 | 0.87 | CYP3A4 (0.39) | FOLH1CYP3A4FAPTTRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230272-A1 | ANTIBODY TARGETING CLDN18.2, BISPECIFIC ANTIBODY, ADC, AND CAR, AND APPLICATIONS THEREOF | L&L BIOPHARMA CO., LTD. (CN) | 2021-07-29 | — | — | US | disclosed |
| US-10543284-B2 | Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof | Suzhou Suncadia Biopharmaceuticals Co., Ltd. (CN) | 2020-01-28 | — | — | US | disclosed |
| US-20180110875-A1 | ANTI-C-MET ANTIBODY AND ANTI-C-MET ANTIBODY-CYTOTOXIC DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10543284-B2 | Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof | MET, HGF, HGFAC | FOLH1 49/4885CYP3A4 1045/4885FAP 442/4885 |
| US-20180110875-A1 | ANTI-C-MET ANTIBODY AND ANTI-C-MET ANTIBODY-CYTOTOXIC DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | MET, HGF, HGFAC | FOLH1 49/4885CYP3A4 1045/4885FAP 442/4885 |
| US-20210230272-A1 | ANTIBODY TARGETING CLDN18.2, BISPECIFIC ANTIBODY, ADC, AND CAR, AND APPLICATIONS THEREOF | VSIG8, IGSF11, CNTN1 | FOLH1 1250/4885CYP3A4 3421/4885FAP 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.